Form 4: Adaptive Biotech CSO Sells Shares Under 10b5-1 Plan

Adaptive Biotechnologies' Chief Scientific Officer, Harlan S. Robins, sold a total of 24,233 shares of common stock in early March 2026 under a pre-arranged trading plan.

Summary

• Harlan S. Robins, Chief Scientific Officer of Adaptive Biotechnologies Corp (ADPT), reported the sale of common stock.
• On March 2, 2026, 10,000 shares were sold at a weighted average price of $15.72 per share, with prices ranging from $15.57 to $15.88.
• On March 3, 2026, an additional 14,233 shares were sold at a weighted average price of $16.52 per share, with prices ranging from $16.50 to $16.55.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robins on August 11, 2025.
• Following these transactions, Mr. Robins beneficially owns 1,155,291 shares of Adaptive Biotechnologies common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sales were conducted under a pre-arranged 10b5-1 trading plan, indicating a planned transaction for diversification or liquidity rather than an immediate reaction to new material non-public information. The volume of shares sold represents a relatively small portion of the officer's total holdings.

Negatives

• A key officer, the Chief Scientific Officer, sold a total of 24,233 shares of common stock.

Industry Context

StockSavvy.ai notes that insider sales, even when conducted under a Rule 10b5-1 trading plan, are routinely monitored by investors. While a 10b5-1 plan indicates a pre-scheduled transaction rather than an immediate reaction to new information, the market often scrutinizes such sales for any potential signals regarding management's long-term confidence or personal financial planning.

Stakeholder Impact

• Shareholders may note the sale of shares by a key executive, though the pre-arranged nature of the transaction under a 10b5-1 plan typically mitigates concerns about its implications for the company's immediate prospects.

Key Dates

Recommendation

The sale of shares by a Chief Scientific Officer, while notable, was executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than a reaction to new material non-public information. This type of insider selling is generally viewed as less impactful than unplanned sales, suggesting a 'hold' recommendation based solely on this filing as it does not present new fundamental information to alter an investment thesis.

Keywords

ADPT, Adaptive Biotechnologies, Harlan S. Robins, Chief Scientific Officer, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan